Details of the Drug Combination

General Information of Drug Combination (ID: DC08DD6)

Drug Combination Name
Bedaquiline Pretomanid
Indication
Disease Entry Status REF
Pulmonary Tuberculosis Phase 1 [1]
Component Drugs Bedaquiline   DM3906J Pretomanid   DMDYA31
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Bedaquiline
Disease Entry ICD 11 Status REF
Drug-resistant tuberculosis N.A. Approved [2]
Multi-drug resistant tuberculosis MG52.00 Approved [3]
Pulmonary tuberculosis 1B10.Z Approved [2]
Bedaquiline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium Proton pump (MycB Prop) TT19K0L A0A1Q4HQH4_9MYCO Modulator [6]
------------------------------------------------------------------------------------
Bedaquiline Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Pretomanid
Disease Entry ICD 11 Status REF
Tuberculosis 1B10-1B14 Approved [4]
Mycobacterium infection 1B10-1B21 Phase 3 [5]
Pretomanid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium Mycolic acid synthase (MycB cma) TT08ESN CMAS1_MYCTU; CMAS2_MYCTU; CMAS3_MYCTU Inhibitor [4]
------------------------------------------------------------------------------------
Pretomanid Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Pulmonary Tuberculosis DCTEABV N. A. Phase 2 [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01215851) Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
2 Bedaquiline FDA Label
3 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 ClinicalTrials.gov (NCT02342886) Shortening Treatment by Advancing Novel Drugs. U.S. National Institutes of Health.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
8 FDA briefing document - pretomanid tablet, 200 mg meeting of the antimicrobial drugs advisory committee (AMDAC).
9 ClinicalTrials.gov (NCT01691534) Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z). U.S. National Institutes of Health.